Cerca una sperimentazione clinica
Altra/e opzione/i di ricerca
32 Risultato/i
Sperimentazione in fase di reclutamento
= 
; Sperimentazione in corso
= 
; Finanziato da un ente associato a IRDiRC = 
Sperimentazioni cliniche nazionali
AUSTRIA
STEIERMARK
GRAZ
An International Prospective Study on Clinically Standard-risk Medulloblastoma in Children Older Than 3 to 5 Years With Low-risk Biological Profile (PNET 5 MB-LR) or Average-risk Biological Profile (PNET 5 MB-SR) (Phase II-III) - AT
Medizinische Universität Graz
Klinische Abteilung für pädiatrische Hämato-Onkologie
AUSTRIA
WIEN
WIEN
An International Prospective Study on Clinically Standard-risk Medulloblastoma in Children Older Than 3 to 5 Years With Low-risk Biological Profile (PNET 5 MB-LR) or Average-risk Biological Profile (PNET 5 MB-SR) (Phase II-III) - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Neonatologie, Pädiatrische Intensivmedizin und Neuropädiatrie
GERMANIA
Hamburg
HAMBURG
PNET 5: An International Prospective Study on Clinically Standard-risk Medulloblastoma in Children Older Than 3 to 5 Years With Low-risk Biological Profile (PNET 5 MB-LR) or Average-risk Biological Profile (PNET 5 MB-SR) (Phase II/III) - DE
UKE - Universitätsklinikum Hamburg-Eppendorf
Klinik und Poliklinik für Pädiatrische Hämatologie und Onkologie
SPAGNA
Madrid
ADDRESS: NOT PROVIDED - ES
An International Prospective Study on Clinically Standard-risk Medulloblastoma in Children Older Than 3 to 5 Years With Low-risk Biological Profile (PNET 5 MB-LR) or Average-risk Biological Profile (PNET 5 MB-SR) (Phase II-III) - ES
Institution: Information not provided - ES
AUSTRIA
OBERÖSTERREICH
LINZ
MEMMAT: A Phase II study of metronomic and targeted anti-angiogenesis therapy for children with recurrent/progressive medulloblastoma - AT
Kepler Universitätsklinikum - Med Campus IV.
Universitätsklinik für Kinder- und Jugendheilkunde
AUSTRIA
SALZBURG
SALZBURG
MEMMAT: A Phase II study of metronomic and targeted anti-angiogenesis therapy for children with recurrent/progressive medulloblastoma - AT
Universitätsklinikum der Paracelsus Medizinischen Privatuniversität
Universitätsklinik für Kinder- und Jugendheilkunde
AUSTRIA
STEIERMARK
GRAZ
MEMMAT: A Phase II study of metronomic and targeted anti-angiogenesis therapy for children with recurrent/progressive medulloblastoma - AT
Medizinische Universität Graz
Klinische Abteilung für pädiatrische Hämato-Onkologie
AUSTRIA
TIROL
INNSBRUCK
MEMMAT: A Phase II study of metronomic and targeted anti-angiogenesis therapy for children with recurrent/progressive medulloblastoma - AT
Medizinische Universität Innsbruck
Pädiatrie I
AUSTRIA
WIEN
WIEN
MEMMAT: A Phase II study of metronomic and targeted anti-angiogenesis therapy for children with recurrent/progressive medulloblastoma - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Neonatologie, Pädiatrische Intensivmedizin und Neuropädiatrie
AUSTRIA
WIEN
WIEN
Phase I/II Open Label, Dose Escalation Trial to Determine the MTD, Safety, PK and Efficacy of Afatinib Monotherapy in Children Aged 1 Year to <18 Years With Recurrent/Refractory Neuroectodermal Tumours, Rhabdomyosarcoma and/or Other Solid Tumours With Known ErbB Pathway Deregulation Regardless of Tumour Histology - AT
St. Anna Kinderspital
Zentrum für Kinder- und Jugendheilkunde
FRANCIA
AUVERGNE-RHONE-ALPES
LYON
MEVITEM: An international, randomized, open-label Phase I/II study of vismodegib in combination with temozolomide versus temozolomide alone in adult patients with recurrent or refractory medulloblastoma presenting an activation of the Sonic Hedgehog pathway - FR
CLCC Léon Bérard
Comité de neuro-oncologie ; Cancérologie médicale - Pédiatrie, Tumeurs cérébrales
FRANCIA
GRAND-EST
NANCY
RSMA2010 : National, Multicentric, Prospective Phase II Study Estimating the Interest of a Dose Decrease for Radiation Therapy Associated With a Carboplatine and Etoposide Based Chemotherapy for the Treatment of Standard Risk Adult Medulloblastomas
CHU de Nancy - Hôpital Central
Service de Neurologie - Unité de Neuro-Oncologie
FRANCIA
ILE-DE-FRANCE
VILLEJUIF
Open Label, Pilot Phase II Study of Glivec in Children and Adolescents with Life Threatening Diseases Known to be associated with one or more Glivec-Sensitive Tyrosine Kinases - FR
CLCC Institut Gustave Roussy
Département de Cancérologie de l'enfant et de l'adolescent
FRANCIA
ILE-DE-FRANCE
VILLEJUIF
Phase 2 single-arm study of gemcitabine in combination with oxaliplatin in refractory and relapsed pediatric solid tumors - Terminated -
CLCC Institut Gustave Roussy
Département de Cancérologie de l'enfant et de l'adolescent
FRANCIA
ILE-DE-FRANCE
VILLEJUIF
Treatment of High-Risk Cerebral Primitive Neuroectodermal Tumors in Children Aged Over 5 Years (Phase II)
CLCC Institut Gustave Roussy
Département de Cancérologie de l'enfant et de l'adolescent
GERMANIA
Bayern
REGENSBURG
NOA-07: Multicentre pilot study for the therapy of Medulloblastoma of the adulthood (Phase II)
Klinik und Poliklinik für Neurologie der Universität Regensburg
Klinik und Poliklinik für Neurologie
GERMANIA
Hamburg
HAMBURG
HIT 2000 Interim: Radiation Therapy and Combination Chemotherapy in Treating Young Patients With Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Ependymoma (Phase III) - DE
UKE - Universitätsklinikum Hamburg-Eppendorf
Klinik und Poliklinik für Pädiatrische Hämatologie und Onkologie
GERMANIA
Nordrhein-Westfalen
ESSEN
HIT-REZ 2005: Therapy-Optimization trial and phase II study for the treatment of relapsed or refractory of primitive neuroectodermal brain tumors and ependymomas in children and adolescents
Universitätsklinikum Essen
Klinik für Kinderheilkunde III - Abteilung für pädiatrische Hämatologie und Onkologie
REGNO UNITO; GRAN BRETAGNA
Greater London
LONDON
A Phase III, multi-center, open-label, randomized, controlled study of the efficacy and safety of oral LDE225 versus temozolomide in patients with Hh-pathway activated relapsed medulloblastoma - UK
University College London Hospitals, NHS Foundation Trust
Haematology and oncology department
SPAGNA
Cataluña
BARCELONA
A Phase 2 clinical study of pomalidomide (CC-4047) monotherapy for children and young adults with recurrent or progressive primary brain tumors - ES
Hospital Universitari Vall d'Hebron
SPAGNA
Cataluña
ESPLUGUES DE LLOBREGAT
A Phase III, Multi-center, Open-label, Randomized, Controlled Study of the Efficacy and Safety of Oral LDE225 Versus Temozolomide in Patients With Hh-pathway Activated Relapsed Medulloblastoma - ES (Completed)
Hospital Sant Joan de Déu Barcelona
Servicio de Oncología y Hematología
SPAGNA
Comunidad Valenciana
VALENCIA
A Phase 2 clinical study of pomalidomide (CC-4047) monotherapy for children and young adults with recurrent or progressive primary brain tumors - ES
Hospital Universitario y Politécnico La Fe
SPAGNA
Madrid
MADRID
A Phase 2 clinical study of pomalidomide (CC-4047) monotherapy for children and young adults with recurrent or progressive primary brain tumors - ES
Hospital Infantil Universitario Niño Jesús
SVIZZERA
Suisse Romande
ADDRESS: NOT PROVIDED - CH
A Phase 2 clinical study of pomalidomide (CC-4047) monotherapy for children and young adults with recurrent or progressive primary brain tumors. -GB
Institution: Information not provided - CH
DANIMARCA
Jylland
ADDRESS: NOT PROVIDED - DK
Phase 1/2 Efficacy, Safety of Plerixafor in Addition to Standard Regimens for Mobilisation of Haematopoietic Stem Cells into Peripheral Blood, and Subsequent Collection by Apheresis, Versus Standard Mobilisation Regimens Alone in Paediatric Patients, with Solid Tumours Eligible for Autologous Transplants - DK
Institution: Information not provided - DK
FRANCIA
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
Phase 1/2 Efficacy, Safety of Plerixafor in Addition to Standard Regimens for Mobilisation of Haematopoietic Stem Cells into Peripheral Blood, and Subsequent Collection by Apheresis, Versus Standard Mobilisation Regimens Alone in Paediatric Patients, with Solid Tumours Eligible for Autologous Transplants - FR
Institution: Information not provided - FR
PAESI BASSI
Noord-Holland
NAARDEN
REGNO UNITO; GRAN BRETAGNA
West Midlands
BIRMINGHAM
Phase 1/2 Efficacy, Safety of Plerixafor in Addition to Standard Regimens for Mobilisation of Haematopoietic Stem Cells into Peripheral Blood, and Subsequent Collection by Apheresis, Versus Standard Mobilisation Regimens Alone in Paediatric Patients, with Solid Tumours Eligible for Autologous Transplants - UK
Birmingham Children's Hospital NHS Foundation Trust
SPAGNA
Cataluña
BARCELONA
A Phase 1/2 Combined Dose Ranging and Randomised, Open-label, Comparative Study of the Efficacy and Safety of Plerixafor in Addition to Standard Regimens for Mobilisation of Haematopoietic Stem Cells into Peripheral Blood [...] in Paediatric Patients, Aged 2 to <18 Years, with Solid Tumours Eligible for Autologous Transplants - ES (completed)
Hospital Universitari Vall d'Hebron
Servicio de Oncología y Hematología Pediátricas
BELGIO
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
STEP: Sorafenib Long Term Extension Program - BE
Cliniques Universitaires UCL Saint-Luc
Pneumologie_Oncologie thoracique
Sperimentazioni cliniche internazionali
GERMANIA
Berlin
BERLIN
HIT 2000: Radiation Therapy and Combination Chemotherapy in Treating Young Patients With Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Ependymoma (Phase III) (coordination)
Gesellschaft für Pädiatrische Onkologie und Hämatologie (GPOH) e.V.
STATI UNITI
Washington
ADDRESS: NOT PROVIDED - US